Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2021 | 2 |
2022 | 3 |
2023 | 1 |
2024 | 1 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma.
Int J Mol Sci. 2022 Oct 21;23(20):12687. doi: 10.3390/ijms232012687.
Int J Mol Sci. 2022.
PMID: 36293545
Free PMC article.
Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH-DR5-B with Dual VEGFR2 and DR5 Receptor Specificity.
Yagolovich AV, Artykov AA, Isakova AA, Vorontsova YV, Dolgikh DA, Kirpichnikov MP, Gasparian ME.
Yagolovich AV, et al. Among authors: artykov aa.
Int J Mol Sci. 2022 May 24;23(11):5860. doi: 10.3390/ijms23115860.
Int J Mol Sci. 2022.
PMID: 35682540
Free PMC article.
Item in Clipboard
Corrigendum: Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL.
Artykov AA, Yagolovich AV, Dolgikh DA, Kirpichnikov MP, Trushina DB, Gasparian ME.
Artykov AA, et al.
Front Cell Dev Biol. 2022 Feb 14;9:820069. doi: 10.3389/fcell.2021.820069. eCollection 2021.
Front Cell Dev Biol. 2022.
PMID: 35237612
Free PMC article.
Item in Clipboard
Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile.
Yagolovich AV, Artykov AA, Karmakova TA, Vorontsova MS, Pankratov AA, Andreev-Andrievsky AA, Dolgikh DA, Kirpichnikov MP, Gasparian ME.
Yagolovich AV, et al. Among authors: artykov aa.
Transl Oncol. 2020 Apr;13(4):100762. doi: 10.1016/j.tranon.2020.100762. Epub 2020 Mar 27.
Transl Oncol. 2020.
PMID: 32224450
Free PMC article.
Item in Clipboard
Dual targeting of DR5 and VEGFR2 molecular pathways by multivalent fusion protein significantly suppresses tumor growth and angiogenesis.
Isakova AA, Artykov AA, Plotnikova EA, Trunova GV, Khokhlova VА, Pankratov AA, Shuvalova ML, Mazur DV, Antipova NV, Shakhparonov MI, Dolgikh DA, Kirpichnikov MP, Gasparian ME, Yagolovich AV.
Isakova AA, et al. Among authors: artykov aa.
Int J Biol Macromol. 2024 Jan;255:128096. doi: 10.1016/j.ijbiomac.2023.128096. Epub 2023 Nov 14.
Int J Biol Macromol. 2024.
PMID: 37972835
Item in Clipboard
Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL.
Artykov AA, Yagolovich AV, Dolgikh DA, Kirpichnikov MP, Trushina DB, Gasparian ME.
Artykov AA, et al.
Front Cell Dev Biol. 2021 Sep 30;9:733688. doi: 10.3389/fcell.2021.733688. eCollection 2021.
Front Cell Dev Biol. 2021.
PMID: 34660590
Free PMC article.
Item in Clipboard
Cite
Cite